Theratechnologies (THTX)
(Real Time Quote from BATS)
$1.30 USD
-0.02 (-1.14%)
Updated Aug 27, 2024 02:45 PM ET
2-Buy of 5 2
C Value A Growth B Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
THTX 1.30 -0.02(-1.14%)
Will THTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for THTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for THTX
Why Fast-paced Mover Theratechnologies (THTX) Is a Great Choice for Value Investors
Despite Fast-paced Momentum, Theratechnologies (THTX) Is Still a Bargain Stock
THTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Theratechnologies (THTX) Is Attractively Priced Despite Fast-paced Momentum
Theratechnologies (THTX) Upgraded to Buy: What Does It Mean for the Stock?
Theratechnologies (THTX) Shows Fast-paced Momentum But Is Still a Bargain Stock
Other News for THTX
Theratechnologies: Fiscal Q2 Earnings Snapshot
Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024
Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update